First Time Loading...

Arcturus Therapeutics Holdings Inc
NASDAQ:ARCT

Watchlist Manager
Arcturus Therapeutics Holdings Inc Logo
Arcturus Therapeutics Holdings Inc
NASDAQ:ARCT
Watchlist
Price: 26.55 USD 1.45% Market Closed
Updated: Apr 27, 2024
Section:
 

Relative Value

The Relative Value of one ARCT stock under the Base Case scenario is 135.52 USD. Compared to the current market price of 26.55 USD, Arcturus Therapeutics Holdings Inc is Undervalued by 80%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ARCT Relative Value
Base Case
135.52 USD
Undervaluation 80%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

4.3
P/S
P/S
Price to Sales
4.3
vs History
76
vs Industry
68
Median 3Y
9.5
Median 5Y
9.5
Industry
8.1
Forward
4.6
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
10
Median 3Y
-3.3
Median 5Y
-6
Industry
26.2
Forward
-11.1
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
13
Median 3Y
-3.6
Median 5Y
-10.7
Industry
22.6
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
10
Median 3Y
-3.5
Median 5Y
-15.2
Industry
21.3
More Details
2.6
P/B
P/B
Price to Book Value
2.6
vs History
79
vs Industry
36
Median 3Y
2.7
Median 5Y
3.3
Industry
2.5
More Details
2.5
EV/S
EV/S
Enterprise Value to Sales
2.5
vs History
77
vs Industry
66
Median 3Y
4.6
Median 5Y
5.2
Industry
7.3
Forward
2.7
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
9.1
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
10
Median 3Y
-1.8
Median 5Y
-3.5
Industry
4.4
Forward
-11.5
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
9
Median 3Y
-1.8
Median 5Y
-3.5
Industry
4.3
Forward
-8.4
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
14
Median 3Y
-1.7
Median 5Y
-6.2
Industry
5.4
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
10
Median 3Y
-1.6
Median 5Y
-6
Industry
3.2
More Details
3.2
EV/IC
EV/IC
Enterprise Value to IC
3.2
vs History
87
vs Industry
41
Median 3Y
5.9
Median 5Y
11.5
Industry
5
More Details

Multiples Across Competitors

ARCT Competitors Multiples
Arcturus Therapeutics Holdings Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Arcturus Therapeutics Holdings Inc
NASDAQ:ARCT
712.3m USD 4.3 -24 -5.6 -5.4
US
Abbvie Inc
NYSE:ABBV
281.9B USD 5.2 58.5 12.7 19.4
US
Amgen Inc
NASDAQ:AMGN
144.5B USD 5.1 21.5 16.1 24.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
102.4B USD 10.4 28.3 22.6 23.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
96.6B USD 7.4 24.4 16.1 17.7
AU
CSL Ltd
ASX:CSL
132B AUD 6.1 34.9 21.2 26.2
US
Gilead Sciences Inc
NASDAQ:GILD
81.5B USD 3 14.4 7.9 10.2
US
Seagen Inc
NASDAQ:SGEN
43.1B USD 18.8 -57.5 -61.9 -55.8
US
Moderna Inc
NASDAQ:MRNA
41.2B USD 6 -8.7 -9.2 -7.8
US
Biogen Inc
NASDAQ:BIIB
30.3B USD 3.1 26.1 14.2 17.6
KR
Celltrion Inc
KRX:068270
36.6T KRW 16.8 68.3 41.9 57.7
EV/EBITDA Multiple
EBITDA Growth
US
Arcturus Therapeutics Holdings Inc
NASDAQ:ARCT
Average EV/EBITDA: 19.1
Negative Multiple: -5.6 		N/A
US
Abbvie Inc
NYSE:ABBV
12.7
26%
US
Amgen Inc
NASDAQ:AMGN
16.1
62%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.6
59%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.1
50%
AU
CSL Ltd
ASX:CSL
21.2
54%
US
Gilead Sciences Inc
NASDAQ:GILD
7.9
18%
US
Seagen Inc
NASDAQ:SGEN
Negative Multiple: -61.9 N/A
US
Moderna Inc
NASDAQ:MRNA
Negative Multiple: -9.2 N/A
US
Biogen Inc
NASDAQ:BIIB
14.2
67%
KR
Celltrion Inc
KRX:068270
41.9
109%

See Also

Summary
ARCT intrinsic value, competitors valuation, and company profile.
DCF Valuation
ARCT stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ARCT stock valuation using valuation multiples.
Wall Street Estimates
ARCT price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ARCT stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 131,800+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.